Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?

M. J. Hjermstad*, H. Holte, S. A. Evensen, P. M. Fayers, S. Kaasa

*Corresponding author for this work

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Health-related quality of life (HRQOL) in leukemia and lymphoma patients treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem cell transplantation or receiving combination chemotherapy (CT) was prospectively assessed by the EORTC QLQ-C30 and compared with reference data from a general population sample. One year after transplant, the SCT group had functional scores which were close to population values except for lower social (P < 0.0001) and role function (P = 0.0004). More symptoms and problems were reported, especially appetite loss (P = 0.001) and financial difficulties (P = 0.0001). The ASCT patients reported a less than optimal HRQOL relative to the population 1 year post transplant. Cognitive, physical, role, and social function, dyspnoea, financial difficulties and global quality of life were most impaired (P < 0.001). In the CT group, physical, role and social function, dyspnoea and financial difficulties were impaired 1 year after start of chemotherapy, compared with the general population (P < 0.001). The EORTC QLQ-C30 was supplemented by a high-dose chemotherapy module, the HDC-19, at the 1-year assessment, but no consistent differences mere found across groups. Fifteen to 34% of the patients expressed fears of relapse and worries about future health, while 24-30% indicated no participation in sexual activities.

Original languageEnglish
Pages (from-to)911-918
Number of pages8
JournalBone Marrow Transplantation
Volume24
Issue number8
DOIs
Publication statusPublished - 5 Oct 1999

Fingerprint

Stem Cell Transplantation
Quality of Life
Drug Therapy
Dyspnea
Population
Transplants
Appetite
Combination Drug Therapy
Sexual Behavior
Fear
Lymphoma
Leukemia
Recurrence
Health

Keywords

  • EORTC QLQ-C30
  • Health-related quality of life
  • High-dose chemotherapy
  • Reference data
  • Stem cell transplantation
  • Treatment side-effects

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? / Hjermstad, M. J.; Holte, H.; Evensen, S. A.; Fayers, P. M.; Kaasa, S.

In: Bone Marrow Transplantation, Vol. 24, No. 8, 05.10.1999, p. 911-918.

Research output: Contribution to journalArticle

@article{3bfac8d5425f4c99b7bd3f29d68bee56,
title = "Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?",
abstract = "Health-related quality of life (HRQOL) in leukemia and lymphoma patients treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem cell transplantation or receiving combination chemotherapy (CT) was prospectively assessed by the EORTC QLQ-C30 and compared with reference data from a general population sample. One year after transplant, the SCT group had functional scores which were close to population values except for lower social (P < 0.0001) and role function (P = 0.0004). More symptoms and problems were reported, especially appetite loss (P = 0.001) and financial difficulties (P = 0.0001). The ASCT patients reported a less than optimal HRQOL relative to the population 1 year post transplant. Cognitive, physical, role, and social function, dyspnoea, financial difficulties and global quality of life were most impaired (P < 0.001). In the CT group, physical, role and social function, dyspnoea and financial difficulties were impaired 1 year after start of chemotherapy, compared with the general population (P < 0.001). The EORTC QLQ-C30 was supplemented by a high-dose chemotherapy module, the HDC-19, at the 1-year assessment, but no consistent differences mere found across groups. Fifteen to 34{\%} of the patients expressed fears of relapse and worries about future health, while 24-30{\%} indicated no participation in sexual activities.",
keywords = "EORTC QLQ-C30, Health-related quality of life, High-dose chemotherapy, Reference data, Stem cell transplantation, Treatment side-effects",
author = "Hjermstad, {M. J.} and H. Holte and Evensen, {S. A.} and Fayers, {P. M.} and S. Kaasa",
note = "Acknowledgements Financial support by grant No. 93094 from the Norwegian Cancer Society. The support from Stein O Kval{\o}y and Lorentz Brinch is greatly appreciated. The Unit for Clinical Research at the Norwegian Radium Hospital has provided excellent help in constructing the databases. Thanks also to Anne Kirsti Blystad for access to the bone marrow registry. The first author is a research fellow employed by the Norwegian Cancer Society.",
year = "1999",
month = "10",
day = "5",
doi = "10.1038/sj.bmt.1701998",
language = "English",
volume = "24",
pages = "911--918",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?

AU - Hjermstad, M. J.

AU - Holte, H.

AU - Evensen, S. A.

AU - Fayers, P. M.

AU - Kaasa, S.

N1 - Acknowledgements Financial support by grant No. 93094 from the Norwegian Cancer Society. The support from Stein O Kvaløy and Lorentz Brinch is greatly appreciated. The Unit for Clinical Research at the Norwegian Radium Hospital has provided excellent help in constructing the databases. Thanks also to Anne Kirsti Blystad for access to the bone marrow registry. The first author is a research fellow employed by the Norwegian Cancer Society.

PY - 1999/10/5

Y1 - 1999/10/5

N2 - Health-related quality of life (HRQOL) in leukemia and lymphoma patients treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem cell transplantation or receiving combination chemotherapy (CT) was prospectively assessed by the EORTC QLQ-C30 and compared with reference data from a general population sample. One year after transplant, the SCT group had functional scores which were close to population values except for lower social (P < 0.0001) and role function (P = 0.0004). More symptoms and problems were reported, especially appetite loss (P = 0.001) and financial difficulties (P = 0.0001). The ASCT patients reported a less than optimal HRQOL relative to the population 1 year post transplant. Cognitive, physical, role, and social function, dyspnoea, financial difficulties and global quality of life were most impaired (P < 0.001). In the CT group, physical, role and social function, dyspnoea and financial difficulties were impaired 1 year after start of chemotherapy, compared with the general population (P < 0.001). The EORTC QLQ-C30 was supplemented by a high-dose chemotherapy module, the HDC-19, at the 1-year assessment, but no consistent differences mere found across groups. Fifteen to 34% of the patients expressed fears of relapse and worries about future health, while 24-30% indicated no participation in sexual activities.

AB - Health-related quality of life (HRQOL) in leukemia and lymphoma patients treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem cell transplantation or receiving combination chemotherapy (CT) was prospectively assessed by the EORTC QLQ-C30 and compared with reference data from a general population sample. One year after transplant, the SCT group had functional scores which were close to population values except for lower social (P < 0.0001) and role function (P = 0.0004). More symptoms and problems were reported, especially appetite loss (P = 0.001) and financial difficulties (P = 0.0001). The ASCT patients reported a less than optimal HRQOL relative to the population 1 year post transplant. Cognitive, physical, role, and social function, dyspnoea, financial difficulties and global quality of life were most impaired (P < 0.001). In the CT group, physical, role and social function, dyspnoea and financial difficulties were impaired 1 year after start of chemotherapy, compared with the general population (P < 0.001). The EORTC QLQ-C30 was supplemented by a high-dose chemotherapy module, the HDC-19, at the 1-year assessment, but no consistent differences mere found across groups. Fifteen to 34% of the patients expressed fears of relapse and worries about future health, while 24-30% indicated no participation in sexual activities.

KW - EORTC QLQ-C30

KW - Health-related quality of life

KW - High-dose chemotherapy

KW - Reference data

KW - Stem cell transplantation

KW - Treatment side-effects

UR - http://www.scopus.com/inward/record.url?scp=0032725492&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701998

DO - 10.1038/sj.bmt.1701998

M3 - Article

VL - 24

SP - 911

EP - 918

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -